238 related articles for article (PubMed ID: 28559424)
1. C-X-C Motif Chemokine Receptor 3 Splice Variants Differentially Activate Beta-Arrestins to Regulate Downstream Signaling Pathways.
Smith JS; Alagesan P; Desai NK; Pack TF; Wu JH; Inoue A; Freedman NJ; Rajagopal S
Mol Pharmacol; 2017 Aug; 92(2):136-150. PubMed ID: 28559424
[TBL] [Abstract][Full Text] [Related]
2. CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways.
Berchiche YA; Sakmar TP
Mol Pharmacol; 2016 Oct; 90(4):483-95. PubMed ID: 27512119
[TBL] [Abstract][Full Text] [Related]
3. Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation.
Smith JS; Nicholson LT; Suwanpradid J; Glenn RA; Knape NM; Alagesan P; Gundry JN; Wehrman TS; Atwater AR; Gunn MD; MacLeod AS; Rajagopal S
Sci Signal; 2018 Nov; 11(555):. PubMed ID: 30401786
[TBL] [Abstract][Full Text] [Related]
4. Functional Analysis of CXCR3 Splicing Variants and Their Ligands Using NanoBiT-Based Molecular Interaction Assays.
Nguyen HT; Hurh S; Nguyen LP; Nguyen TU; Park HK; Seong JY; Lee CS; Ham BJ; Hwang JI
Mol Cells; 2023 May; 46(5):281-297. PubMed ID: 36799104
[TBL] [Abstract][Full Text] [Related]
5. Disparate roles of CXCR3A and CXCR3B in regulating progressive properties of colorectal cancer cells.
Li H; Rong S; Chen C; Fan Y; Chen T; Wang Y; Chen D; Yang C; Yang J
Mol Carcinog; 2019 Feb; 58(2):171-184. PubMed ID: 30302818
[TBL] [Abstract][Full Text] [Related]
6. GPCR kinases differentially modulate biased signaling downstream of CXCR3 depending on their subcellular localization.
Gardner J; Eiger DS; Hicks C; Choi I; Pham U; Chundi A; Namjoshi O; Rajagopal S
Sci Signal; 2024 Feb; 17(823):eadd9139. PubMed ID: 38349966
[TBL] [Abstract][Full Text] [Related]
7. Location bias contributes to functionally selective responses of biased CXCR3 agonists.
Eiger DS; Boldizsar N; Honeycutt CC; Gardner J; Kirchner S; Hicks C; Choi I; Pham U; Zheng K; Warman A; Smith JS; Zhang JY; Rajagopal S
Nat Commun; 2022 Oct; 13(1):5846. PubMed ID: 36195635
[TBL] [Abstract][Full Text] [Related]
8. Biased agonism as a mechanism for differential signaling by chemokine receptors.
Rajagopal S; Bassoni DL; Campbell JJ; Gerard NP; Gerard C; Wehrman TS
J Biol Chem; 2013 Dec; 288(49):35039-48. PubMed ID: 24145037
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding.
Gustavsson M; Dyer DP; Zhao C; Handel TM
Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506383
[TBL] [Abstract][Full Text] [Related]
10. Atypical Chemokine Receptor 3 "Senses" CXC Chemokine Receptor 4 Activation Through GPCR Kinase Phosphorylation.
Schafer CT; Chen Q; Tesmer JJG; Handel TM
Mol Pharmacol; 2023 Oct; 104(4):174-186. PubMed ID: 37474305
[TBL] [Abstract][Full Text] [Related]
11. Carboxy-Terminal Phosphoregulation of the Long Splice Isoform of Free-Fatty Acid Receptor-4 Mediates
Senatorov IS; Cheshmehkani A; Burns RN; Singh K; Moniri NH
Mol Pharmacol; 2020 May; 97(5):304-313. PubMed ID: 32132133
[TBL] [Abstract][Full Text] [Related]
12. Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands.
Littmann T; Göttle M; Reinartz MT; Kälble S; Wainer IW; Ozawa T; Seifert R
J Pharmacol Exp Ther; 2015 Nov; 355(2):183-90. PubMed ID: 26306764
[TBL] [Abstract][Full Text] [Related]
13. Conformational Sensors and Domain Swapping Reveal Structural and Functional Differences between β-Arrestin Isoforms.
Ghosh E; Dwivedi H; Baidya M; Srivastava A; Kumari P; Stepniewski T; Kim HR; Lee MH; van Gastel J; Chaturvedi M; Roy D; Pandey S; Maharana J; Guixà-González R; Luttrell LM; Chung KY; Dutta S; Selent J; Shukla AK
Cell Rep; 2019 Sep; 28(13):3287-3299.e6. PubMed ID: 31553900
[TBL] [Abstract][Full Text] [Related]
14. CXCR3A contributes to the invasion and metastasis of gastric cancer cells.
Yang C; Zheng W; Du W
Oncol Rep; 2016 Sep; 36(3):1686-92. PubMed ID: 27461521
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation barcodes direct biased chemokine signaling at CXCR3.
Eiger DS; Smith JS; Shi T; Stepniewski TM; Tsai CF; Honeycutt C; Boldizsar N; Gardner J; Nicora CD; Moghieb AM; Kawakami K; Choi I; Hicks C; Zheng K; Warman A; Alagesan P; Knape NM; Huang O; Silverman JD; Smith RD; Inoue A; Selent J; Jacobs JM; Rajagopal S
Cell Chem Biol; 2023 Apr; 30(4):362-382.e8. PubMed ID: 37030291
[TBL] [Abstract][Full Text] [Related]
16. S-Nitrosylation of β-Arrestins Biases Receptor Signaling and Confers Ligand Independence.
Hayashi H; Hess DT; Zhang R; Sugi K; Gao H; Tan BL; Bowles DE; Milano CA; Jain MK; Koch WJ; Stamler JS
Mol Cell; 2018 May; 70(3):473-487.e6. PubMed ID: 29727618
[TBL] [Abstract][Full Text] [Related]
17. C-X-C motif receptor 3A enhances proliferation and invasiveness of colorectal cancer cells, and is mediated by C-X-C motif ligand 10.
Nozaki E; Kobayashi T; Ohnishi H; Ohtsuka K; Masaki T; Watanabe T; Sugiyama M
Oncol Lett; 2020 Mar; 19(3):2495-2501. PubMed ID: 32194750
[TBL] [Abstract][Full Text] [Related]
18. Selective regulation of recombinantly expressed mGlu7 metabotropic glutamate receptors by G protein-coupled receptor kinases and arrestins.
Iacovelli L; Felicioni M; Nisticò R; Nicoletti F; De Blasi A
Neuropharmacology; 2014 Feb; 77():303-12. PubMed ID: 24148810
[TBL] [Abstract][Full Text] [Related]
19. Ligand-biased and probe-dependent modulation of chemokine receptor CXCR3 signaling by negative allosteric modulators.
Bernat V; Brox R; Heinrich MR; Auberson YP; Tschammer N
ChemMedChem; 2015 Mar; 10(3):566-74. PubMed ID: 25655398
[TBL] [Abstract][Full Text] [Related]
20. Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis.
Furuya M; Yoneyama T; Miyagi E; Tanaka R; Nagahama K; Miyagi Y; Nagashima Y; Hirahara F; Inayama Y; Aoki I
Gynecol Oncol; 2011 Sep; 122(3):648-55. PubMed ID: 21684584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
